Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 9/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29842783 | 0.89 | IMPDH2 (0.48) | IMPDH2KDM4EMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL16207483 | 0.89 | IMPDH2 (0.48) | IMPDH2KDM4EMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL7291390 | 0.88 | PDE3B (0.51) | IMPDH2KDM4EMAPK1ALDH1A1MAPT | |
| SCHEMBL7294056 | 0.87 | IMPDH2 (0.49) | IMPDH2KDM4EMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL372048 | 0.87 | IMPDH2 (0.58) | IMPDH2KDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL7284981 | 0.86 | IMPDH2 (0.50) | IMPDH2KDM4EMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL7290454 | 0.86 | IMPDH2 (0.50) | IMPDH2KDM4EMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL15275124 | 0.86 | IMPDH2 (0.50) | IMPDH2KDM4EMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL1892646 | 0.82 | PRKCQ (0.40) | IMPDH2ALDH1A1 | |
| SCHEMBL1894760 | 0.82 | PRKAB2 (0.49) | IMPDH2KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0343574-B1 | 4(1H)-quinolone derivatives | KIRIN BREWERY (JP) | 1994-07-27 | — | — | EP | claimed |
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| EP-0343574-B1 | 4(1H)-quinolone derivatives | KIRIN BREWERY (JP) | 1994-07-27 | — | — | EP | disclosed |
| US-5081121-A | Cardiotonic agents | KIRIN BEER KABUSHIKI KAISHA (JP) | 1992-01-14 | — | — | US | disclosed |
| EP-0343574-A1 | 4(1H)-quinolone derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | IMPDH2 2971/4885KDM4E 1380/4885MAPK1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.